Success Metrics

Active Trials
9(90%)

Phase Distribution

Ph phase_2
7
70%
Ph phase_3
1
10%
Ph phase_1
2
20%

Phase Distribution

2

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
7(70.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

9

trials recruiting

Total Trials

10

all time

Status Distribution
Active(10)

Detailed Status

Recruiting8
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
9
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (20.0%)
Phase 27 (70.0%)
Phase 31 (10.0%)

Trials by Status

active_not_recruiting110%
not_yet_recruiting110%
recruiting880%

Recent Activity

9 active trials
Showing 5 of 10
recruitingphase_2

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

NCT06632977
active_not_recruitingphase_1

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

NCT05682443
recruitingphase_1

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT07219147
recruitingphase_2

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

NCT06526299
recruitingphase_2

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

NCT06288113
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06632977Phase 2

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Recruiting
NCT05682443Phase 1

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Active Not Recruiting
NCT07219147Phase 1

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Recruiting
NCT06526299Phase 2

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

Recruiting
NCT06288113Phase 2

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Recruiting
NCT06216249Phase 2

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Recruiting
NCT06145633Phase 2

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Recruiting
NCT07150715Phase 2

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

Recruiting
NCT07200830Phase 3

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Not Yet Recruiting
NCT06200103Phase 2

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Recruiting

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10